On August 29, TUL held its 2025 Mid-Year Results Press Conference in Hong Kong. At the conference, it was announced that Federal Pharmaceutical's operating revenue for the first half of 2025 reached 7.519 billion yuan, representing a year-on-year increase of 4.8%. The profit attributable to owners of the parent company stood at 1.894 billion yuan, a year-on-year growth of 27.0%, achieving sustained and steady improvement in overall operations.